NASDAQ:DFTX Definium Therapeutics (DFTX) Stock Price, News & Analysis $36.90 +2.72 (+7.96%) As of 10/9/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Definium Therapeutics Stock (NASDAQ:DFTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Definium Therapeutics alerts:Sign Up Key Stats Today's Range$34.57▼$38.0450-Day Range$34.18▼$46.1852-Week Range$10.46▼$49.70Volume2.77 million shsAverage Volume2.61 million shsMarket Capitalization$4.96 billionP/E RatioN/ADividend YieldN/APrice Target$66.00Consensus RatingBuy Company Overview Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. AI Generated. May Contain Errors. Read More Definium Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreDFTX MarketRank™: Definium Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 217th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDefinium Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 19 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDefinium Therapeutics has a consensus price target of $66.00, representing about 78.9% upside from its current price of $36.90.Amount of Analyst CoverageDefinium Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Definium Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Definium Therapeutics are expected to grow in the coming year, from ($3.02) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Definium Therapeutics is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Definium Therapeutics is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDefinium Therapeutics has a P/B Ratio of 10.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.65% of the float of Definium Therapeutics has been sold short.Short Interest Ratio / Days to CoverDefinium Therapeutics has a short interest ratio ("days to cover") of 4.89.Change versus previous monthShort interest in Definium Therapeutics has recently decreased by 3.74%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDefinium Therapeutics does not currently pay a dividend.Dividend GrowthDefinium Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentDefinium Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Definium Therapeutics this week, compared to 8 articles on an average week.Search Interest19 people have searched for DFTX on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows18 people have added Definium Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,700% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Definium Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,626,115.00 in company stock.Percentage Held by Insiders2.40% of the stock of Definium Therapeutics is held by insiders.Percentage Held by Institutions27.91% of the stock of Definium Therapeutics is held by institutions.Read more about Definium Therapeutics' insider trading history. Receive DFTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Definium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DFTX Stock News HeadlinesJPMorgan Chase & Co. Begins Coverage on Definium Therapeutics (NASDAQ:DFTX)October 11 at 1:30 AM | americanbankingnews.comDefinium Therapeutics consensus price target raised 12.21% to $73.32October 2, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 11 at 1:00 AM | Weiss Ratings (Ad)Definium Therapeutics (NASDAQ:DFTX) Stock: Insider Matthew Wiley Sells 3,097 SharesOctober 1, 2026 | americanbankingnews.comDefinium Therapeutics (NASDAQ:DFTX) Stock: Insider Mark Sullivan Sells 14,051 SharesOctober 1, 2026 | americanbankingnews.comDefinium Therapeutics (NASDAQ:DFTX) Stock: Insider Robert Barrow Sells 31,550 SharesOctober 1, 2026 | americanbankingnews.comDefinium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC FilingSeptember 30, 2026 | finance.yahoo.comDefinium Therapeutics (NASDAQ:DFTX) Insider Matthew Wiley Sells 3,097 Shares of Company StockSeptember 30, 2026 | insidertrades.comSee More Headlines DFTX Stock Analysis - Frequently Asked Questions How have DFTX shares performed this year? Definium Therapeutics' stock was trading at $13.39 at the beginning of 2026. Since then, DFTX stock has increased by 175.6% and is now trading at $36.90. How were Definium Therapeutics' earnings last quarter? Definium Therapeutics, Inc. (NASDAQ:DFTX) announced its earnings results on Thursday, August, 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.89. Read the conference call transcript. When did Definium Therapeutics' stock split? Definium Therapeutics shares reverse split before market open on Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Definium Therapeutics' major shareholders? Top institutional investors of Definium Therapeutics include Stableford Capital II LLC (0.02%), Farther Finance Advisors LLC (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Robert Barrow, Mark Sullivan, Daniel Karlin, Brandi Roberts, Matthew T Wiley, Dan Karlin, Schond L Greenway, Carrie Liao and David W Gryska. View institutional ownership trends. How do I buy shares of Definium Therapeutics? Shares of DFTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Definium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Definium Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Tesla (TSLA) and Company Calendar Last Earnings8/06/2026Today10/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DFTX's financial health is in the Green zone, according to TradeSmith. DFTX has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DFTX Previous SymbolNASDAQ:MNMD CIK1813814 Webmindmed.co Phone212 220 6633FaxN/AEmployees40Year Founded2019Price Target and Rating Average Price Target for Definium Therapeutics$66.00 High Price Target$90.00 Low Price Target$25.00 Potential Upside/Downside+78.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.01% Return on Assets-63.66% Debt Debt-to-Equity Ratio0.04 Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book10.98Miscellaneous Outstanding Shares134,370,000Free Float131,142,000Market Cap$4.96 billion OptionableOptionable Beta2.19 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:DFTX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Definium Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Definium Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
